SCHEMBL5797490

SCHEMBL5797490

O=CC1(CCCCCCO)CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.44
CYP4A11 Q02928 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20730066 0.82 CYP4F2 (0.35) CYP4F2CYP4A11
SCHEMBL11503129 0.79 TSHR (0.38)
SCHEMBL9646862 0.79 TSHR (0.38)
SCHEMBL22336042 0.78 CYP4F2 (0.33) CYP4F2CYP4A11
SCHEMBL2236262 0.77 TSHR (0.34)
SCHEMBL341390 0.75 CYP2C19 (0.30)
SCHEMBL3728108 0.74 CYP4F2 (0.32) CYP4F2CYP4A11
SCHEMBL9173367 0.74 CETP (0.33)
SCHEMBL10304508 0.73 HTT (0.30)
SCHEMBL5187599 0.73 CYP4F2 (0.46) CYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4208063-B1 DISPENSING PACKAGE AND METHOD FOR CONTROLLED DELIVERY OF A VISCOUS COMPOSITION PROCTER & GAMBLE (US) 2024-12-11 EP claimed
US-11857056-B2 Dispensing package and method for controlled delivery of a viscous composition THE PROCTER & GAMBLE COMPANY (US) 2024-01-02 US claimed
EP-4208063-A2 DISPENSING PACKAGE AND METHOD FOR CONTROLLED DELIVERY OF A VISCOUS COMPOSITION The Procter & Gamble Company (US) 2023-07-12 EP claimed
WO-2022051059-A2 DISPENSING PACKAGE AND METHOD FOR CONTROLLED DELIVERY OF A VISCOUS COMPOSITION THE PROCTER & GAMBLE COMPANY (US) 2022-03-10 WO claimed
US-20220061498-A1 Dispensing Package And Method For Controlled Delivery Of A Viscous Composition THE PROCTER & GAMBLE COMPANY 2022-03-03 US claimed
US-10682383-B2 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY (US) 2020-06-16 US claimed
US-20190111095-A1 Personal Care Compositions With Improved Hyposensitivity PROCTER & GAMBLE (US) 2019-04-18 US claimed
EP-1666021-B1 Personal care compositions with improved hyposensitivity PROCTER & GAMBLE (US) 2015-07-01 EP claimed
EP-1666021-A1 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY (US) 2006-06-07 EP claimed
WO-2006014447-A1 PERSONAL CARE COMPOSITIONS WITH IMPROVED HYPOSENSITIVITY THE PROCTER & GAMBLE COMPANY (US) 2006-02-09 WO claimed
US-20060002876-A1 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY 2006-01-05 US claimed
EP-4208063-B1 DISPENSING PACKAGE AND METHOD FOR CONTROLLED DELIVERY OF A VISCOUS COMPOSITION PROCTER & GAMBLE (US) 2024-12-11 EP disclosed
US-11857056-B2 Dispensing package and method for controlled delivery of a viscous composition THE PROCTER & GAMBLE COMPANY (US) 2024-01-02 US disclosed
US-20220061498-A1 Dispensing Package And Method For Controlled Delivery Of A Viscous Composition THE PROCTER & GAMBLE COMPANY 2022-03-03 US disclosed
US-10682383-B2 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY (US) 2020-06-16 US disclosed
US-8455417-B2 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY (US) 2013-06-04 US disclosed
US-20120270932-A1 Personal Care Compositions with Improved Hyposensitivity CAHEN CHRISTINE MARIE (GB) 2012-10-25 US disclosed
EP-1666021-A1 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY (US) 2006-06-07 EP disclosed
WO-2006014447-A1 PERSONAL CARE COMPOSITIONS WITH IMPROVED HYPOSENSITIVITY THE PROCTER & GAMBLE COMPANY (US) 2006-02-09 WO disclosed
US-20060002876-A1 Personal care compositions with improved hyposensitivity THE PROCTER & GAMBLE COMPANY 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220061498-A1 Dispensing Package And Method For Controlled Delivery Of A Viscous Composition ADRA1D, ADRA1A, USE1 CYP4F2 3921/4885CYP4A11 1910/4885
US-10682383-B2 Personal care compositions with improved hyposensitivity CUTA, DPM1, PIEZO1 CYP4F2 4433/4885CYP4A11 2770/4885
US-20060002876-A1 Personal care compositions with improved hyposensitivity CUTA, DPM1, PIEZO1 CYP4F2 4433/4885CYP4A11 2770/4885
US-20120270932-A1 Personal Care Compositions with Improved Hyposensitivity CUTA, DPM1, PIEZO1 CYP4F2 4433/4885CYP4A11 2770/4885
US-11857056-B2 Dispensing package and method for controlled delivery of a viscous composition ADRA1D, ADRA1A, USE1 CYP4F2 4026/4885CYP4A11 2120/4885
US-20190111095-A1 Personal Care Compositions With Improved Hyposensitivity CUTA, DPM1, PIEZO1 CYP4F2 4433/4885CYP4A11 2770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.